Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon’s comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.
LightArray operates a comprehensive drug development services laboratory in Wuxi, China and will now provide researchers with a local, centralized protein biomarker testing laboratory employing Aushon’s protein biomarker technologies including:
• A growing menu of 300+ validated assays
• Multiplex biomarker sample testing service
• Multiplex protein biomarker kits
• Custom arrays and assay development
• Array imaging and analysis systems
“Our strategic partnership with LightArray enables companies located in China and involved in pre-clinical and clinical research to take advantage of our full range of biomarker products and services, including our flexible sample testing service and growing menu of more than 300 biomarkers in key therapeutic areas such as oncology, inflammation, cardiovascular disease, and diabetes,” said Pete Honkanen, CEO of Aushon. “They can also count on the same exacting level of reliability, performance and support that we deliver to our current customers in the United States, Europe and Southeast Asia.”
“We are extremely excited by the opportunity to assist Aushon in bringing their portfolio of multiplex biomarker services and products into the emerging China market,” said Alan Zhang, President and CEO of LightArray. “The adoption of biomarkers as a critical research tool in pre-clinical and clinical studies is growing rapidly in China, and our ability to provide local, regional access to the proven Aushon multiplex technology platform will be vital. We also look forward to providing the same unrivaled service and support to our customers that Aushon has built its reputation on.”
Date: December 1, 2010
Source: Aushon BioSystems, Inc.
